These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

240 related items for PubMed ID: 22506598

  • 21. ALK rearrangement in a large series of consecutive non-small cell lung cancers: comparison between a new immunohistochemical approach and fluorescence in situ hybridization for the screening of patients eligible for crizotinib treatment.
    Alì G, Proietti A, Pelliccioni S, Niccoli C, Lupi C, Sensi E, Giannini R, Borrelli N, Menghi M, Chella A, Ribechini A, Cappuzzo F, Melfi F, Lucchi M, Mussi A, Fontanini G.
    Arch Pathol Lab Med; 2014 Nov; 138(11):1449-58. PubMed ID: 24885803
    [Abstract] [Full Text] [Related]

  • 22. K-RAS mutations indicating primary resistance to crizotinib in ALK-rearranged adenocarcinomas of the lung: Report of two cases and review of the literature.
    Mengoli MC, Barbieri F, Bertolini F, Tiseo M, Rossi G.
    Lung Cancer; 2016 Mar; 93():55-8. PubMed ID: 26898615
    [Abstract] [Full Text] [Related]

  • 23. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer.
    Doebele RC, Pilling AB, Aisner DL, Kutateladze TG, Le AT, Weickhardt AJ, Kondo KL, Linderman DJ, Heasley LE, Franklin WA, Varella-Garcia M, Camidge DR.
    Clin Cancer Res; 2012 Mar 01; 18(5):1472-82. PubMed ID: 22235099
    [Abstract] [Full Text] [Related]

  • 24. Heterogeneity of genetic changes associated with acquired crizotinib resistance in ALK-rearranged lung cancer.
    Kim S, Kim TM, Kim DW, Go H, Keam B, Lee SH, Ku JL, Chung DH, Heo DS.
    J Thorac Oncol; 2013 Apr 01; 8(4):415-22. PubMed ID: 23344087
    [Abstract] [Full Text] [Related]

  • 25. Concomitant ALK translocation and EGFR mutation in lung cancer: a comparison of direct sequencing and sensitive assays and the impact on responsiveness to tyrosine kinase inhibitor.
    Won JK, Keam B, Koh J, Cho HJ, Jeon YK, Kim TM, Lee SH, Lee DS, Kim DW, Chung DH.
    Ann Oncol; 2015 Feb 01; 26(2):348-54. PubMed ID: 25403583
    [Abstract] [Full Text] [Related]

  • 26. Atypical negative ALK break-apart FISH harboring a crizotinib-responsive ALK rearrangement in non-small-cell lung cancer.
    Ren S, Hirsch FR, Varella-Garcia M, Aisner DL, Boyle T, Zhou C, Camidge DR.
    J Thorac Oncol; 2014 Mar 01; 9(3):e21-3. PubMed ID: 24518095
    [No Abstract] [Full Text] [Related]

  • 27. Native and rearranged ALK copy number and rearranged cell count in non-small cell lung cancer: implications for ALK inhibitor therapy.
    Camidge DR, Skokan M, Kiatsimkul P, Helfrich B, Lu X, Barón AE, Schulte N, Maxson D, Aisner DL, Franklin WA, Doebele RC, Varella-Garcia M.
    Cancer; 2013 Nov 15; 119(22):3968-75. PubMed ID: 24022839
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. De novo ALK kinase domain mutations are uncommon in kinase inhibitor-naïve ALK rearranged lung cancers.
    Lucena-Araujo AR, Moran JP, VanderLaan PA, Dias-Santagata D, Folch E, Majid A, Kent MS, Gangadharan SP, Rangachari D, Huberman MS, Kobayashi SS, Costa DB.
    Lung Cancer; 2016 Sep 15; 99():17-22. PubMed ID: 27565908
    [Abstract] [Full Text] [Related]

  • 31. Crizotinib for the treatment of ALK-rearranged non-small cell lung cancer: a success story to usher in the second decade of molecular targeted therapy in oncology.
    Ou SH, Bartlett CH, Mino-Kenudson M, Cui J, Iafrate AJ.
    Oncologist; 2012 Sep 15; 17(11):1351-75. PubMed ID: 22989574
    [Abstract] [Full Text] [Related]

  • 32. Comprehensive Genomic Profiling Identifies a Subset of Crizotinib-Responsive ALK-Rearranged Non-Small Cell Lung Cancer Not Detected by Fluorescence In Situ Hybridization.
    Ali SM, Hensing T, Schrock AB, Allen J, Sanford E, Gowen K, Kulkarni A, He J, Suh JH, Lipson D, Elvin JA, Yelensky R, Chalmers Z, Chmielecki J, Peled N, Klempner SJ, Firozvi K, Frampton GM, Molina JR, Menon S, Brahmer JR, MacMahon H, Nowak J, Ou SH, Zauderer M, Ladanyi M, Zakowski M, Fischbach N, Ross JS, Stephens PJ, Miller VA, Wakelee H, Ganesan S, Salgia R.
    Oncologist; 2016 Jun 15; 21(6):762-70. PubMed ID: 27245569
    [Abstract] [Full Text] [Related]

  • 33. New strategies for treatment of ALK-rearranged non-small cell lung cancers.
    Sasaki T, Jänne PA.
    Clin Cancer Res; 2011 Dec 01; 17(23):7213-8. PubMed ID: 22010214
    [Abstract] [Full Text] [Related]

  • 34. ROS1 rearrangements define a unique molecular class of lung cancers.
    Bergethon K, Shaw AT, Ou SH, Katayama R, Lovly CM, McDonald NT, Massion PP, Siwak-Tapp C, Gonzalez A, Fang R, Mark EJ, Batten JM, Chen H, Wilner KD, Kwak EL, Clark JW, Carbone DP, Ji H, Engelman JA, Mino-Kenudson M, Pao W, Iafrate AJ.
    J Clin Oncol; 2012 Mar 10; 30(8):863-70. PubMed ID: 22215748
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. ALK inhibitors in non-small cell lung cancer: crizotinib and beyond.
    Awad MM, Shaw AT.
    Clin Adv Hematol Oncol; 2014 Jul 10; 12(7):429-39. PubMed ID: 25322323
    [Abstract] [Full Text] [Related]

  • 38. ALK-rearranged squamous cell lung carcinoma responding to crizotinib: A missing link in the field of non-small cell lung cancer?
    Vergne F, Quéré G, Andrieu-Key S, Descourt R, Quintin-Roué I, Talagas M, De Braekeleer M, Marcorelles P, Uguen A.
    Lung Cancer; 2016 Jan 10; 91():67-9. PubMed ID: 26603857
    [Abstract] [Full Text] [Related]

  • 39. Crizotinib as a personalized alternative for targeted anaplastic lymphoma kinase rearrangement in previously treated patients with non-small-cell lung cancer.
    Guo L, Zhang H, Shao W, Chen B.
    Drug Des Devel Ther; 2015 Jan 10; 9():5491-7. PubMed ID: 26491259
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.